{"id":"W4309017270","doi":"10.1093/neuonc/noac209.295","title":"CTNI-30. LOGGIC/FIREFLY-2: A PHASE 3, RANDOMIZED TRIAL OF TOVORAFENIB VS. CHEMOTHERAPY IN PEDIATRIC PATIENTS WITH NEWLY DIAGNOSED LOW-GRADE GLIOMA HARBORING AN ACTIVATING RAF ALTERATION","year":2022,"lang":"en","type":"article","venue":"Neuro-Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Medicine; Tolerability; Regimen; Internal medicine; Chemotherapy regimen; Clinical endpoint; Oncology; Chemotherapy; Randomized controlled trial; Phases of clinical research; Glioma; Adverse effect; Cancer research","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005990618,0.0003148323,0.001275403,0.0005402232,0.0001463635,0.00002061495,0.000150093,0.0001178087,0.0002337951],"category_scores_gemma":[0.0004281593,0.0002586118,0.0001829126,0.0006872497,0.0000738871,0.0001631115,0.00006632355,0.0003881236,0.000002492137],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004355519,"about_ca_system_score_gemma":0.0003555085,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001118985,"about_ca_topic_score_gemma":0.00001822321,"domain_scores_codex":[0.9966998,0.0009355958,0.0008551823,0.0005802293,0.0005218036,0.0004074404],"domain_scores_gemma":[0.9973003,0.001399234,0.0006493278,0.0003721885,0.0001056437,0.0001733206],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8914549,0.02473257,0.02225177,0.00006352941,0.0001480429,0.001035773,0.001818601,0.000433165,0.0418135,0.00004249109,0.0001374484,0.01606817],"study_design_scores_gemma":[0.9599651,0.01803972,0.004899719,0.00002027109,0.0002533164,0.00001938603,0.00008363232,0.001167632,0.01484032,0.0000267143,0.0004809204,0.0002032547],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9941132,0.00007055348,0.00002707236,0.001011203,0.0005034922,0.004087873,0.00001880842,0.00006073876,0.0001070642],"genre_scores_gemma":[0.9967068,0.00007335213,0.000385439,0.0006835622,0.0003508016,0.001598625,0.0001393799,0.00006025391,0.000001777327],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.06851017,"threshold_uncertainty_score":0.9999866,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01657756764545945,"score_gpt":0.3039716173841623,"score_spread":0.2873940497387029,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}